Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.30), $0.14 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $247.22 million versus the consensus estimate of $242.08 million.

GUIDANCE:

Tandem Diabetes sees FY2026 revenue of $1.06-1.08 billion, versus the consensus of $1.07 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.